Free Trial
→ Trump Makes Major Crypto Announcement (From Crypto 101 Media) (Ad) Buy MPW Stock  Free MPW Stock Alerts

Medical Properties Trust (MPW) Financials

Medical Properties Trust logo
$4.57 -0.04 (-0.87%)
Closing price 05/30/2025 03:59 PM Eastern
Extended Trading
$4.61 +0.04 (+0.77%)
As of 05/30/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Medical Properties Trust

Annual Income Statements for Medical Properties Trust

This table shows Medical Properties Trust's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders		 -2,410 -556 903 656 431 375 1,017 290 225 140
Consolidated Net Income / (Loss)		 -2,408 -556 904 657 432 376 1,018 291 226 140
Net Income / (Loss) Continuing Operations		 -2,408 -556 904 657 432 376 1,018 291 226 140
Total Pre-Tax Income 		-2,364 -687 960 731 463 374 1,019 294 219 140
Total Revenue		 996 872 1,543 1,177 921 616 785 705 541 442
Net Interest Income / (Expense)		 0.00 0.00 0.00 -367 -329 -238 162 0.00 0.00 0.00
Total Interest Income		 0.00 0.00 0.00 0.00 0.00 0.00 162 0.00 0.00 0.00
Total Interest Expense		 0.00 0.00 0.00 367 329 238 0.00 0.00 0.00 0.00
Total Non-Interest Income		 996 872 1,543 1,545 1,249 854 622 705 541 442
Other Service Charges		 49 69 166 169 142 150 - 129 108 112
Other Non-Interest Income		 947 803 1,377 1,376 1,107 704 622 576 433 330
Total Non-Interest Expense		 1,027 1,202 898 506 421 294 495 396 359 179
Net Occupancy & Equipment Expense		 27 42 46 - - - - - - 3.79
Other Operating Expenses		 552 557 520 185 157 120 314 241 211 44
Depreciation Expense		 448 603 333 321 264 152 133 125 94 70
Nonoperating Income / (Expense), net		 -2,333 -357 315 60 -36 51 729 -15 37 -123
Income Tax Expense		 44 -131 56 74 31 -2.62 0.93 2.68 -6.83 -
Net Income / (Loss) Attributable to Noncontrolling Interest		 1.98 0.38 1.22 0.92 0.82 1.72 1.79 1.45 0.89 0.33
Basic Earnings per Share		 ($4.02) ($0.93) $1.50 $1.11 $0.81 $0.87 $2.77 $0.82 $0.86 $0.64
Weighted Average Basic Shares Outstanding		 600.25M 598.52M 598.63M 588.82M 529.24M 427.08M 365.36M 349.90M 260.41M 218.00M
Diluted Earnings per Share		 ($4.02) ($0.93) $1.50 $1.11 $0.81 $0.87 $2.76 $0.82 $0.86 $0.63
Weighted Average Diluted Shares Outstanding		 600.25M 598.52M 598.84M 590.14M 530.46M 428.30M 366.27M 350.44M 261.07M 218.30M
Weighted Average Basic & Diluted Shares Outstanding		 600.60M 599.10M 598.30M 599.90M 580M 520.93M 367M 353.40M 261.70M 218.10M
Cash Dividends to Common per Share		 $0.38 $1.17 $1.15 $1.11 $1.07 $1.01 $0.99 $0.95 $0.90 $0.87

Quarterly Income Statements for Medical Properties Trust

This table shows Medical Properties Trust's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -413 -801 -321 -876 -664 117 -42 33 -140 222
Consolidated Net Income / (Loss)		 -412 -801 -320 -875 -664 117 -42 33 -140 222
Net Income / (Loss) Continuing Operations		 -412 -801 -320 -875 -664 117 -42 33 -140 222
Total Pre-Tax Income 		-403 -792 -305 -864 -660 127 -191 37 -125 241
Total Revenue		 440 120 165 271 -16 200 337 350 469 264
Net Interest Income / (Expense)		 197 -106 -101 11 75 -107 0.00 32 88 -88
Total Interest Income		 -11 0.00 0.00 11 -32 0.00 0.00 32 - 0.00
Total Interest Expense		 -208 106 101 0.00 -107 107 0.00 0.00 -88 88
Total Non-Interest Income		 243 226 267 260 -90 307 337 318 380 352
Other Non-Interest Income		 220 216 250 260 -69 277 277 318 339 310
Total Non-Interest Expense		 412 246 145 222 320 122 529 230 312 127
Other Operating Expenses		 320 42 43 147 201 45 165 146 185 46
Depreciation Expense		 65 205 102 76 77 78 364 84 81 82
Nonoperating Income / (Expense), net		 -430 -665 -325 -913 -324 49 1.06 -83 -286 104
Income Tax Expense		 9.56 9.03 15 11 3.98 10 -148 3.54 15 19
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.53 0.23 0.98 0.25 0.36 0.19 -0.40 0.24 0.26 0.23
Basic Earnings per Share		 ($0.68) ($1.34) ($0.54) ($1.46) ($1.10) $0.19 ($0.07) $0.05 ($0.24) $0.37
Weighted Average Basic Shares Outstanding		 600.25M 600.23M 600.06M 600.30M 598.52M 598.44M 598.34M 598.30M 598.63M 598.98M
Diluted Earnings per Share		 ($0.68) ($1.34) ($0.54) ($1.46) ($1.10) $0.19 ($0.07) $0.05 ($0.24) $0.37
Weighted Average Diluted Shares Outstanding		 600.25M 600.23M 600.06M 600.30M 598.52M 598.55M 598.34M 598.31M 598.84M 599.34M
Weighted Average Basic & Diluted Shares Outstanding		 600.60M 600.40M 600.20M 600.10M 599.10M 599M 598.40M 598.30M 598.30M 598M

Annual Cash Flow Statements for Medical Properties Trust

This table details how cash moves in and out of Medical Properties Trust's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 84 3.02 -207 -99 -928 652 667 70 -110 62
Net Cash From Operating Activities		 245 506 739 812 618 494 449 362 264 207
Net Cash From Continuing Operating Activities		 245 506 739 812 618 499 449 362 264 207
Net Income / (Loss) Continuing Operations		 -2,408 -556 904 657 432 376 1,018 291 226 140
Consolidated Net Income / (Loss)		 -2,408 -556 904 657 432 376 1,018 291 226 140
Depreciation Expense		 454 616 346 334 276 157 141 132 98 72
Amortization Expense		 17 16 17 17 13 8.88 7.36 6.52 7.61 6.09
Non-Cash Adjustments to Reconcile Net Income		 2,198 555 -441 -209 -101 -95 906 -44 -76 -26
Changes in Operating Assets and Liabilities, net		 -16 -125 -87 13 -2.60 53 -34 -24 9.13 15
Net Cash From Investing Activities		 1,318 518 396 -3,858 -2,947 -4,884 564 -2,362 -927 -1,946
Net Cash From Continuing Investing Activities		 1,318 518 396 -3,858 -2,947 -4,884 564 -2,362 -927 -1,946
Purchase of Property, Leasehold Improvements and Equipment		 -80 -114 -109 -68 -68 -84 - -74 -171 -146
Purchase of Investment Securities		 -682 -780 -1,748 -5,698 -4,348 -4,913 - -2,361 -1,911 -2,590
Sale and/or Maturity of Investments		 2,080 1,412 2,253 1,908 1,470 113 4,181 73 1,156 791
Net Cash From Financing Activities		 -1,479 -1,020 -1,343 2,948 1,401 5,042 -346 2,070 553 1,801
Net Cash From Continuing Financing Activities		 -1,479 -1,020 -1,343 2,948 1,812 5,042 -252 2,070 553 1,801
Net Change in Deposits		 2.24 10 -5.02 18 22 -12 21 28 15 -11
Issuance of Debt		 804 568 129 3,968 2,379 2,983 760 2,906 1,000 1,190
Issuance of Common Equity		 0.00 0.00 0.00 1,051 411 2,533 188 548 1,174 817
Repayment of Debt		 -1,833 -988 -666 -1,391 -800 0.00 -812 -1,038 -1,385 -0.28
Repurchase of Common Equity		 0.00 0.00 -18 0.00 0.00 - - - - -
Payment of Dividends		 -321 -615 -699 -643 -568 -412 364 -327 -218 -183
Other Financing Activities, Net		 -132 5.18 -84 -54 369 -50 -3.61 -46 -32 -13
Cash Interest Paid		 420 406 354 326 310 211 222 150 278 214

Quarterly Cash Flow Statements for Medical Properties Trust

This table details how cash moves in and out of Medical Properties Trust's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 69 -345 384 -23 -97 30 6.53 64 -80 57
Net Cash From Operating Activities		 77 59 35 74 135 158 77 136 181 214
Net Cash From Continuing Operating Activities		 77 59 35 74 135 158 77 136 181 214
Net Income / (Loss) Continuing Operations		 -412 -801 -320 -875 -664 117 -42 33 -140 222
Consolidated Net Income / (Loss)		 -412 -801 -320 -875 -664 117 -42 33 -140 222
Depreciation Expense		 66 206 104 77 80 81 368 88 85 85
Amortization Expense		 5.08 4.78 3.79 3.70 3.80 3.88 4.08 4.01 3.92 3.90
Non-Cash Adjustments to Reconcile Net Income		 386 623 308 881 727 -20 -181 29 251 -100
Changes in Operating Assets and Liabilities, net		 32 26 -61 -12 -12 -23 -72 -18 -18 3.02
Net Cash From Investing Activities		 92 144 1,202 -119 170 -62 392 17 -462 324
Net Cash From Continuing Investing Activities		 92 144 1,202 -119 170 -62 392 17 -462 324
Purchase of Property, Leasehold Improvements and Equipment		 -16 -18 -15 -30 -34 -52 -15 -13 -11 -6.62
Purchase of Investment Securities		 16 -186 -289 -222 -106 -232 -250 -192 -452 -83
Sale and/or Maturity of Investments		 92 348 1,507 133 310 223 657 222 1.01 414
Net Cash From Financing Activities		 -100 -548 -854 22 -403 -67 -462 -89 201 -481
Net Cash From Continuing Financing Activities		 -100 -548 -854 22 -403 -67 -462 -89 201 -481
Net Change in Deposits		 2.96 -9.23 2.28 6.23 2.39 0.60 9.85 -2.69 -2.43 -5.77
Repayment of Debt		 -51 -401 -1,381 0.00 -454 -319 -215 0.00 204 -201
Payment of Dividends		 -48 -90 -90 -93 -91 -174 -174 -177 -174 -174
Other Financing Activities, Net		 -3.76 -48 -78 -2.57 -0.98 -0.72 13 -5.77 -0.63 -36
Cash Interest Paid		 71 95 123 132 84 95 111 116 68 76

Annual Balance Sheets for Medical Properties Trust

This table presents Medical Properties Trust's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 14,295 18,305 19,658 20,520 16,829 14,467 8,844 9,020 6,419 5,609
Cash and Due from Banks		 332 250 236 459 550 1,462 821 171 83 196
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Mortgage Servicing Rights		 120 309 364 213 248 1,275 1,213 1,778 1,060 758
Other Assets		 2,375 2,663 5,381 3,239 2,964 2,934 1,156 1,369 1,043 1,433
Total Liabilities & Shareholders' Equity		 14,295 18,305 19,658 20,520 16,829 14,467 8,844 9,020 6,419 5,609
Total Liabilities		 9,461 10,671 11,064 12,074 9,485 7,439 4,283 5,185 3,165 3,502
Long-Term Debt		 8,848 10,064 10,268 11,283 8,865 7,024 4,037 4,899 2,909 3,323
Other Long-Term Liabilities		 613 607 174 791 181 554 41 229 20 29
Total Equity & Noncontrolling Interests		 4,834 7,634 8,594 8,446 7,344 7,028 4,561 3,835 3,253 2,107
Total Preferred & Common Equity		 4,833 7,632 8,593 8,440 7,339 7,028 4,547 3,821 3,248 2,102
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 4,833 7,632 8,593 8,440 7,339 14,119 4,547 3,821 3,248 2,102
Common Stock		 8,586 8,561 8,536 8,565 7,462 14,029 4,443 4,333 3,776 2,594
Retained Earnings		 -3,659 -972 116 -88 -71 83 163 -486 -434 -419
Accumulated Other Comprehensive Income / (Loss)		 -94 43 -59 -37 -51 -63 -58 -26 -93 -73
Noncontrolling Interest		 1.05 2.27 1.57 5.48 5.33 0.11 14 15 4.85 5.00

Quarterly Balance Sheets for Medical Properties Trust

This table presents Medical Properties Trust's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 15,236 16,195 17,301 19,005 19,204 19,650 19,043
Cash and Due from Banks		 276 607 224 340 324 302 299
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 11,654 11,949 - - - 11,885 -
Mortgage Servicing Rights		 298 399 310 302 299 346 306
Intangible Assets		 -1,424 -1,418 11,401 11,727 11,882 - 11,994
Other Assets		 4,432 4,658 5,366 6,635 6,699 3,418 6,444
Total Liabilities & Shareholders' Equity		 15,236 16,195 17,301 19,005 19,204 19,650 19,043
Total Liabilities		 9,795 10,002 10,597 10,719 10,890 11,207 10,210
Other Short-Term Payables		 418 447 303 376 445 - 569
Long-Term Debt		 9,216 9,369 10,099 10,157 10,238 10,438 9,476
Other Long-Term Liabilities		 161 186 195 186 207 769 165
Total Equity & Noncontrolling Interests		 5,441 6,193 6,704 8,285 8,315 8,443 8,833
Total Preferred & Common Equity		 5,439 6,190 6,702 8,285 8,314 8,442 8,832
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 5,439 6,190 6,702 8,285 8,314 8,442 8,832
Common Stock		 8,579 8,572 8,568 8,559 8,548 8,542 8,538
Retained Earnings		 -3,198 -2,348 -1,847 -215 -241 -25 433
Accumulated Other Comprehensive Income / (Loss)		 57 -34 -19 -60 6.68 -75 -139
Noncontrolling Interest		 2.54 2.90 2.27 0.89 0.90 1.57 1.47

Annual Metrics And Ratios for Medical Properties Trust

This table displays calculated financial ratios and metrics derived from Medical Properties Trust's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 14.19% -43.49% 31.05% 27.89% 49.34% -21.43% 11.32% 30.23% 22.46% 41.39%
EBITDA Growth		 45.73% -70.02% -1.43% 29.56% 61.61% 11.24% -1.87% 55.66% -15.80% 67.87%
EBIT Growth		 90.61% -151.17% -3.97% 34.34% 54.89% 11.28% -6.06% 69.54% -30.85% 84.14%
NOPAT Growth		 90.61% -138.04% 0.62% 29.42% 43.50% 12.16% -5.28% 62.91% -28.69% 84.14%
Net Income Growth		 -333.07% -161.53% 37.58% 51.97% 14.84% -63.04% 249.71% 28.90% 61.47% 175.47%
EPS Growth		 -332.26% -162.00% 35.14% 37.04% -6.90% -68.48% 236.59% -4.65% 36.51% 117.24%
Operating Cash Flow Growth		 -51.47% -31.56% -8.95% 31.41% 25.00% 10.03% 23.98% 37.29% 27.46% 37.59%
Free Cash Flow Firm Growth		 327.77% -36.59% 150.51% -72.40% 67.02% -1,306.17% 118.77% -315.65% 66.14% -148.49%
Invested Capital Growth		 -22.69% -6.17% -4.39% 21.71% 15.35% 63.43% -1.55% 41.72% 13.50% 52.66%
Revenue Q/Q Growth		 84.24% -35.71% 27.47% 12.52% 12.28% -30.94% -3.01% 7.91% 42.10% -16.50%
EBITDA Q/Q Growth		 389.35% -62.20% -3.10% 4.48% 28.43% -0.49% -12.92% 69.77% -19.11% -20.00%
EBIT Q/Q Growth		 92.13% -303.67% -4.25% 4.65% 40.56% -4.07% -17.61% 128.39% -29.21% -25.82%
NOPAT Q/Q Growth		 92.12% -309.59% -6.24% 7.16% 40.19% -69.18% -20.23% 126.31% -27.00% -25.82%
Net Income Q/Q Growth		 9.45% -1,599.55% -27.75% 18.19% 14.80% -7.14% 0.65% 11.11% 10.18% 11.69%
EPS Q/Q Growth		 9.46% -1,228.57% -28.23% 15.63% 19.12% -13.86% 0.73% 9.33% 4.88% 0.00%
Operating Cash Flow Q/Q Growth		 -19.31% -8.28% -6.70% 7.80% 1.43% 3.51% 1.74% 14.81% 8.53% 10.76%
Free Cash Flow Firm Q/Q Growth		 13.79% 4,172.58% 15.25% 1.93% 43.40% -105.26% -16.01% 39.41% -158.34% 23.18%
Invested Capital Q/Q Growth		 -6.65% -4.04% 3.02% 4.16% 5.23% 16.29% 0.80% 0.70% 28.40% -0.86%
Profitability Metrics		 - - - - - - - - - -
EBITDA Margin		 44.21% 34.64% 65.29% 86.80% 85.69% 79.19% 55.93% 63.45% 53.08% 77.20%
EBIT Margin		 -3.11% -37.84% 41.78% 57.02% 54.29% 52.34% 36.95% 43.79% 33.64% 59.57%
Profit (Net Income) Margin		 -241.91% -63.79% 58.58% 55.80% 46.96% 61.07% 129.82% 41.33% 41.75% 31.67%
Tax Burden Percent		 101.87% 80.97% 94.18% 89.88% 93.30% 100.70% 99.91% 99.09% 103.12% 100.00%
Interest Burden Percent		 7,631.82% 208.18% 148.88% 108.88% 92.72% 115.86% 351.62% 95.23% 120.36% 53.16%
Effective Tax Rate		 0.00% 0.00% 5.82% 10.12% 6.70% -0.70% 0.09% 0.91% -3.12% 0.00%
Return on Invested Capital (ROIC)		 -0.14% -1.26% 3.15% 3.36% 3.08% 2.87% 3.34% 4.11% 3.24% 5.86%
ROIC Less NNEP Spread (ROIC-NNEP)		 -25.38% -4.46% 5.90% 3.89% 2.65% 3.80% 19.65% 3.73% 4.47% 1.37%
Return on Net Nonoperating Assets (RNNOA)		 -38.49% -5.59% 7.46% 4.96% 2.93% 3.63% 20.92% 4.11% 5.19% 2.16%
Return on Equity (ROE)		 -38.63% -6.85% 10.61% 8.32% 6.02% 6.50% 24.26% 8.22% 8.43% 8.02%
Cash Return on Invested Capital (CROIC)		 25.46% 5.11% 7.63% -16.23% -11.18% -45.29% 4.91% -30.42% -9.40% -35.83%
Operating Return on Assets (OROA)		 -0.19% -1.74% 3.21% 3.59% 3.19% 2.77% 3.25% 4.00% 3.03% 5.64%
Return on Assets (ROA)		 -14.78% -2.93% 4.50% 3.52% 2.76% 3.23% 11.40% 3.77% 3.76% 3.00%
Return on Common Equity (ROCE)		 -38.62% -6.85% 10.60% 8.32% 8.98% 10.46% 24.18% 8.19% 8.41% 8.01%
Return on Equity Simple (ROE_SIMPLE)		 -49.83% -7.29% 10.52% 7.78% 5.89% 5.36% 22.40% 7.62% 6.96% 6.66%
Net Operating Profit after Tax (NOPAT)		 -22 -231 607 603 466 325 290 306 188 263
NOPAT Margin		 -2.18% -26.49% 39.35% 51.25% 50.65% 52.71% 36.92% 43.39% 34.69% 59.57%
Net Nonoperating Expense Percent (NNEP)		 25.24% 3.20% -2.75% -0.53% 0.43% -0.93% -16.31% 0.37% -1.23% 4.49%
SG&A Expenses to Revenue		 2.74% 4.77% 2.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.86%
Operating Expenses to Revenue		 103.11% 137.84% 58.22% 42.98% 45.71% 47.66% 63.05% 56.21% 66.36% 40.43%
Earnings before Interest and Taxes (EBIT)		 -31 -330 645 671 500 323 290 309 182 263
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 440 302 1,007 1,022 789 488 439 447 287 341
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.49 0.35 0.63 1.29 1.17 0.54 0.85 0.81 0.69 0.70
Price to Tangible Book Value (P/TBV)		 0.49 0.35 0.73 1.29 1.40 0.56 0.92 0.90 0.76 0.78
Price to Revenue (P/Rev)		 2.38 3.07 3.49 9.26 9.32 12.33 4.93 4.38 4.17 3.31
Price to Earnings (P/E)		 0.00 0.00 5.96 16.63 19.88 20.29 3.81 10.66 10.02 10.48
Dividend Yield		 11.65% 19.71% 12.90% 6.12% 6.75% 6.94% 9.43% 11.31% 12.93% 14.31%
Earnings Yield		 0.00% 0.00% 16.78% 6.01% 5.03% 4.93% 26.27% 9.38% 9.98% 9.54%
Enterprise Value to Invested Capital (EV/IC)		 0.80 0.71 0.82 1.10 1.04 0.94 0.83 0.90 0.83 0.85
Enterprise Value to Revenue (EV/Rev)		 10.94 14.33 9.99 18.46 18.36 21.36 9.05 11.11 9.40 10.40
Enterprise Value to EBITDA (EV/EBITDA)		 24.74 41.36 15.30 21.27 21.42 26.97 16.18 17.52 17.70 13.47
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 23.91 32.38 33.82 40.80 24.49 25.38 27.94 17.46
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 25.39 36.02 36.25 40.52 24.51 25.61 27.09 17.46
Enterprise Value to Operating Cash Flow (EV/OCF)		 44.36 24.70 20.86 26.78 27.36 26.64 15.81 21.62 19.28 22.20
Enterprise Value to Free Cash Flow (EV/FCFF)		 2.73 13.38 10.47 0.00 0.00 0.00 16.70 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 1.83 1.32 1.19 1.34 1.21 1.00 0.89 1.28 0.89 1.58
Long-Term Debt to Equity		 1.83 1.32 1.19 1.34 1.21 1.00 0.89 1.28 0.89 1.58
Financial Leverage		 1.52 1.25 1.26 1.28 1.11 0.95 1.06 1.10 1.16 1.58
Leverage Ratio		 2.61 2.34 2.36 2.37 2.18 2.01 2.13 2.18 2.24 2.67
Compound Leverage Factor		 199.55 4.87 3.51 2.58 2.02 2.33 7.48 2.07 2.70 1.42
Debt to Total Capital		 64.67% 56.87% 54.44% 57.19% 54.69% 49.98% 46.96% 56.09% 47.21% 61.19%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 64.67% 56.87% 54.44% 57.19% 54.69% 49.98% 46.96% 56.09% 47.21% 61.19%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.01% 0.01% 0.01% 0.03% 0.03% 0.00% 0.16% 0.17% 0.08% 0.09%
Common Equity to Total Capital		 35.32% 43.12% 45.55% 42.78% 45.27% 100.48% 52.88% 43.75% 52.71% 38.72%
Debt to EBITDA		 20.10 33.32 10.19 11.04 11.24 14.39 9.20 10.96 10.13 9.74
Net Debt to EBITDA		 19.35 32.50 9.96 10.59 10.54 11.39 7.33 10.57 9.84 9.17
Long-Term Debt to EBITDA		 20.10 33.32 10.19 11.04 11.24 14.39 9.20 10.96 10.13 9.74
Debt to NOPAT		 -408.04 -43.58 16.91 18.70 19.02 21.62 13.94 16.02 15.50 12.62
Net Debt to NOPAT		 -392.71 -42.50 16.53 17.94 17.84 17.12 11.10 15.46 15.06 11.88
Long-Term Debt to NOPAT		 -408.04 -43.58 16.91 18.70 19.02 21.62 13.94 16.02 15.50 12.62
Noncontrolling Interest Sharing Ratio		 0.03% 0.02% 0.04% 0.07% -49.30% -61.07% 0.34% 0.27% 0.18% 0.14%
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 3,995 934 1,473 -2,916 -1,691 -5,129 425 -2,265 -545 -1,610
Operating Cash Flow to CapEx		 307.67% 442.02% 676.52% 1,198.46% 903.64% 589.65% 0.00% 490.75% 154.10% 141.42%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -7.94 -5.14 -21.56 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 2.21 1.88 2.08 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 2.02 1.67 1.73 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.06 0.05 0.08 0.06 0.06 0.05 0.09 0.09 0.09 0.09
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.10 0.10 0.16 0.15 0.16 0.18
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 13,682 17,698 18,863 19,728 16,209 14,052 8,598 8,734 6,163 5,430
Invested Capital Turnover		 0.06 0.05 0.08 0.07 0.06 0.05 0.09 0.09 0.09 0.10
Increase / (Decrease) in Invested Capital		 -4,016 -1,165 -866 3,519 2,157 5,454 -136 2,571 733 1,873
Enterprise Value (EV)		 10,888 12,491 15,413 21,736 16,898 13,163 7,100 7,832 5,085 4,595
Market Capitalization		 2,372 2,675 5,378 10,907 8,577 7,601 3,870 3,090 2,255 1,463
Book Value per Share		 $8.05 $12.74 $14.37 $14.15 $13.69 $27.29 $12.46 $10.49 $10.14 $8.84
Tangible Book Value per Share		 $8.05 $12.74 $12.35 $14.15 $11.46 $26.21 $11.49 $9.41 $9.32 $7.86
Total Capital		 13,682 17,698 18,863 19,728 16,209 14,052 8,598 8,734 6,163 5,430
Total Debt		 8,848 10,064 10,268 11,283 8,865 7,024 4,037 4,899 2,909 3,323
Total Long-Term Debt		 8,848 10,064 10,268 11,283 8,865 7,024 4,037 4,899 2,909 3,323
Net Debt		 8,516 9,814 10,033 10,824 8,316 5,561 3,217 4,727 2,826 3,127
Capital Expenditures (CapEx)		 80 114 109 68 68 84 -54 74 171 146
Net Nonoperating Expense (NNE)		 2,387 325 -297 -54 34 -52 -729 15 -38 123
Net Nonoperating Obligations (NNO)		 8,848 10,064 10,268 11,283 8,865 7,024 4,037 4,899 2,909 3,323
Total Depreciation and Amortization (D&A)		 471 632 363 351 289 165 149 139 105 78
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($4.02) ($0.93) $1.50 $1.11 $0.81 $0.87 $2.77 $0.82 $0.86 $0.64
Adjusted Weighted Average Basic Shares Outstanding		 600.25M 598.52M 598.63M 588.82M 529.24M 427.08M 365.36M 349.90M 260.41M 218.00M
Adjusted Diluted Earnings per Share		 ($4.02) ($0.93) $1.50 $1.11 $0.81 $0.87 $2.76 $0.82 $0.86 $0.63
Adjusted Weighted Average Diluted Shares Outstanding		 600.25M 598.52M 598.84M 590.14M 530.46M 428.30M 366.27M 350.44M 261.07M 218.30M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $1.11 $0.00 $0.87 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 600.60M 599.10M 598.30M 599.90M 580M 520.93M 381.08M 364.69M 320.93M 237.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -22 -231 607 603 466 241 338 335 165 227
Normalized NOPAT Margin		 -2.18% -26.49% 39.35% 51.25% 50.65% 39.03% 43.03% 47.56% 30.47% 51.42%
Pre Tax Income Margin		 -237.48% -78.78% 62.20% 62.08% 50.33% 60.64% 129.94% 41.71% 40.49% 31.67%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 1.83 1.52 1.36 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 1.64 1.42 1.37 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 1.64 1.31 1.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 1.46 1.21 1.01 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 -13.33% -110.66% 77.29% 97.95% 131.39% 109.38% -35.73% 112.19% 96.66% 130.77%
Augmented Payout Ratio		 -13.33% -110.66% 79.27% 97.95% 131.39% 109.38% -35.73% 112.19% 96.66% 130.77%

Quarterly Metrics And Ratios for Medical Properties Trust

This table displays calculated financial ratios and metrics derived from Medical Properties Trust's official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 2,904.12% -40.17% -51.06% -22.53% -103.35% -24.37% -15.70% -14.54% 244.35% -10.92%
EBITDA Growth		 139.10% -47.94% -29.25% -38.62% -202.68% -28.11% -30.50% -23.75% -11.63% -13.53%
EBIT Growth		 108.09% -263.81% 110.38% -59.22% -314.50% -43.37% -214.03% -34.60% -15.46% -18.46%
NOPAT Growth		 108.09% -224.54% 110.38% -68.39% -308.02% -43.49% -184.29% -38.23% -38.45% -20.11%
Net Income Growth		 37.86% -785.17% -653.33% -2,750.25% -373.27% -47.35% -122.33% -94.77% -167.79% 29.54%
EPS Growth		 38.18% -805.26% -671.43% -3,020.00% -358.33% -48.65% -121.88% -95.24% -168.57% 27.59%
Operating Cash Flow Growth		 -43.37% -62.58% -53.93% -45.19% -25.22% -26.04% -53.51% -24.38% -22.66% 0.79%
Free Cash Flow Firm Growth		 333.94% 6,084.82% 844.25% 699.61% -4.97% -108.16% 154.74% 135.59% 129.33% 122.40%
Invested Capital Growth		 -22.69% -20.53% -16.12% -11.01% -6.17% 0.73% -2.38% -0.82% -4.39% -3.33%
Revenue Q/Q Growth		 267.54% -27.58% -39.14% 1,830.99% -107.84% -40.76% -3.66% -25.26% 77.31% -33.97%
EBITDA Q/Q Growth		 16.72% -33.88% -1.73% 151.56% -255.40% -10.15% -14.74% -13.75% 8.80% -13.13%
EBIT Q/Q Growth		 121.40% -737.74% -59.29% 114.57% -533.01% 140.40% -259.98% -23.36% 14.32% -18.65%
NOPAT Q/Q Growth		 121.40% -737.74% -59.29% 114.58% -429.19% 153.14% -224.00% 1.86% -10.58% -20.72%
Net Income Q/Q Growth		 48.52% -150.56% 63.48% -31.92% -667.68% 375.48% -228.47% 123.56% -163.15% 16.81%
EPS Q/Q Growth		 49.25% -148.15% 63.01% -32.73% -678.95% 371.43% -240.00% 120.83% -164.86% 15.63%
Operating Cash Flow Q/Q Growth		 29.55% 67.89% -52.57% -45.10% -14.40% 106.71% -43.58% -25.10% -15.34% 29.93%
Free Cash Flow Firm Q/Q Growth		 9.15% 23.06% 42.20% 127.13% 1,605.42% -119.42% 20.42% -72.82% 29.33% 230.18%
Invested Capital Q/Q Growth		 -6.65% -5.82% -7.39% -5.06% -4.04% -0.59% -1.74% 0.10% 3.02% -3.66%
Profitability Metrics		 - - - - - - - - - -
EBITDA Margin		 22.40% 70.53% 77.24% 47.84% 0.00% 81.05% 53.44% 60.38% 52.33% 85.27%
EBIT Margin		 6.18% -106.13% 12.05% 18.02% 0.00% 38.76% -56.83% 34.23% 33.38% 51.77%
Profit (Net Income) Margin		 -93.81% -669.76% -193.58% -322.64% 0.00% 58.49% -12.58% 9.43% -29.92% 84.01%
Tax Burden Percent		 102.37% 101.14% 104.77% 101.27% 100.60% 92.08% 22.25% 90.31% 112.24% 92.28%
Interest Burden Percent		 -1,483.29% 623.98% -1,533.18% -1,768.51% 196.62% 163.87% 99.45% 30.51% -79.88% 175.87%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 7.92% 0.00% 9.69% 0.00% 7.72%
Return on Invested Capital (ROIC)		 0.27% -2.43% 0.31% 0.56% 0.00% 2.63% -3.01% 2.42% 1.93% 3.10%
ROIC Less NNEP Spread (ROIC-NNEP)		 -4.29% -9.78% -3.10% -8.30% 0.00% 3.10% -2.11% 1.69% -0.42% 4.06%
Return on Net Nonoperating Assets (RNNOA)		 -6.50% -13.80% -4.18% -11.25% 0.00% 3.55% -2.50% 2.00% -0.53% 4.74%
Return on Equity (ROE)		 -6.23% -16.22% -3.88% -10.69% 0.00% 6.19% -5.51% 4.41% 1.39% 7.84%
Cash Return on Invested Capital (CROIC)		 25.46% 21.21% 16.75% 10.08% 5.11% -0.12% 3.22% 3.45% 7.63% 6.86%
Operating Return on Assets (OROA)		 0.38% -3.35% 0.42% 0.77% 0.00% 2.76% -4.15% 2.57% 2.56% 3.23%
Return on Assets (ROA)		 -5.73% -21.14% -6.79% -13.85% 0.00% 4.17% -0.92% 0.71% -2.30% 5.25%
Return on Common Equity (ROCE)		 -6.23% -16.22% -3.88% -10.69% 0.00% 6.19% -5.51% 6.68% 1.39% 7.84%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -48.90% -28.14% -21.85% 0.00% -0.40% 0.87% 3.61% 0.00% 14.16%
Net Operating Profit after Tax (NOPAT)		 19 -89 14 34 -235 71 -134 108 113 126
NOPAT Margin		 4.32% -74.29% 8.44% 12.61% 0.00% 35.69% -39.78% 30.91% 24.09% 47.77%
Net Nonoperating Expense Percent (NNEP)		 4.56% 7.35% 3.40% 8.86% 4.22% -0.46% -0.90% 0.73% 2.35% -0.96%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 93.82% 206.13% 87.95% 81.98% 0.00% 61.24% 156.83% 65.77% 66.62% 48.23%
Earnings before Interest and Taxes (EBIT)		 27 -127 20 49 -335 77 -192 120 156 137
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 98 84 128 130 -252 162 180 211 245 225
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.49 0.65 0.42 0.40 0.35 0.35 0.60 0.50 0.63 0.66
Price to Tangible Book Value (P/TBV)		 0.49 0.51 0.34 0.00 0.35 0.00 0.00 0.50 0.73 0.00
Price to Revenue (P/Rev)		 2.38 6.50 4.17 3.35 3.07 2.17 3.49 2.87 3.49 4.80
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 68.74 14.03 5.96 4.65
Dividend Yield		 11.65% 9.06% 13.92% 19.86% 19.71% 20.79% 14.01% 16.29% 12.90% 11.86%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.45% 7.13% 16.78% 21.51%
Enterprise Value to Invested Capital (EV/IC)		 0.80 0.85 0.73 0.75 0.71 0.69 0.80 0.76 0.82 0.82
Enterprise Value to Revenue (EV/Rev)		 10.94 23.05 18.29 15.80 14.33 9.41 10.47 9.71 9.99 12.38
Enterprise Value to EBITDA (EV/EBITDA)		 24.74 138.47 67.73 56.87 41.36 15.96 17.24 15.29 15.30 14.42
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 78.74 67.19 24.77 23.91 22.26
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 115.76 98.01 28.91 25.39 23.14
Enterprise Value to Operating Cash Flow (EV/OCF)		 44.36 40.94 28.15 28.19 24.70 23.13 24.49 20.71 20.86 18.92
Enterprise Value to Free Cash Flow (EV/FCFF)		 2.73 3.55 3.97 6.97 13.38 0.00 24.61 22.01 10.47 11.73
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 1.83 1.69 1.51 1.51 1.32 1.23 1.23 1.24 1.19 1.07
Long-Term Debt to Equity		 1.83 1.69 1.51 1.51 1.32 1.23 1.23 1.24 1.19 1.07
Financial Leverage		 1.52 1.41 1.35 1.36 1.25 1.15 1.19 1.18 1.26 1.17
Leverage Ratio		 2.61 2.49 2.44 2.44 2.34 2.22 2.27 2.27 2.36 2.25
Compound Leverage Factor		 -38.78 15.57 -37.41 -43.14 4.60 3.64 2.25 0.69 -1.88 3.96
Debt to Total Capital		 64.67% 62.88% 60.20% 60.10% 56.87% 55.07% 55.18% 55.28% 54.44% 51.76%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 64.67% 62.88% 60.20% 60.10% 56.87% 55.07% 55.18% 55.28% 54.44% 51.76%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.01% 0.02% 0.02% 0.01% 0.01% 0.00% 0.00% 0.01% 0.01% 0.01%
Common Equity to Total Capital		 35.32% 37.11% 39.78% 39.89% 43.12% 44.92% 44.81% 44.71% 45.55% 48.24%
Debt to EBITDA		 20.10 102.47 55.90 45.83 33.32 12.71 11.87 11.09 10.19 9.12
Net Debt to EBITDA		 19.35 99.40 52.28 44.81 32.50 12.29 11.50 10.77 9.96 8.83
Long-Term Debt to EBITDA		 20.10 102.47 55.90 45.83 33.32 12.71 11.87 11.09 10.19 9.12
Debt to NOPAT		 -408.04 -33.47 -70.84 -36.01 -43.58 92.19 67.48 20.95 16.91 14.63
Net Debt to NOPAT		 -392.71 -32.47 -66.26 -35.21 -42.50 89.10 65.35 20.35 16.53 14.17
Long-Term Debt to NOPAT		 -408.04 -33.47 -70.84 -36.01 -43.58 92.19 67.48 20.95 16.91 14.63
Noncontrolling Interest Sharing Ratio		 0.03% 0.02% 0.03% 0.03% 0.00% 0.01% 0.04% -51.33% 0.04% 0.04%
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 4,035 3,697 3,004 2,113 930 -62 318 264 979 757
Operating Cash Flow to CapEx		 471.83% 320.77% 232.03% 248.76% 401.63% 303.81% 498.66% 1,020.52% 1,581.06% 3,233.06%
Free Cash Flow to Firm to Interest Expense		 0.00 34.80 29.62 0.00 0.00 -0.58 0.00 0.00 0.00 8.59
Operating Cash Flow to Interest Expense		 0.00 0.56 0.35 0.00 0.00 1.48 0.00 0.00 0.00 2.43
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.38 0.20 0.00 0.00 0.99 0.00 0.00 0.00 2.35
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.06 0.03 0.04 0.04 0.05 0.07 0.07 0.08 0.08 0.06
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 13,682 14,657 15,562 16,803 17,698 18,442 18,552 18,881 18,863 18,309
Invested Capital Turnover		 0.06 0.03 0.04 0.04 0.05 0.07 0.08 0.08 0.08 0.07
Increase / (Decrease) in Invested Capital		 -4,016 -3,786 -2,990 -2,078 -1,165 133 -452 -156 -866 -630
Enterprise Value (EV)		 10,888 12,454 11,352 12,531 12,491 12,754 14,869 14,399 15,413 14,987
Market Capitalization		 2,372 3,511 2,586 2,655 2,675 2,936 4,955 4,261 5,378 5,808
Book Value per Share		 $8.05 $9.06 $10.32 $11.19 $12.74 $13.84 $13.90 $14.11 $14.37 $14.74
Tangible Book Value per Share		 $8.05 $11.43 $12.68 ($7.84) $12.74 ($5.75) ($5.96) $14.11 $12.35 ($5.28)
Total Capital		 13,682 14,657 15,562 16,803 17,698 18,442 18,552 18,881 18,863 18,309
Total Debt		 8,848 9,216 9,369 10,099 10,064 10,157 10,238 10,438 10,268 9,476
Total Long-Term Debt		 8,848 9,216 9,369 10,099 10,064 10,157 10,238 10,438 10,268 9,476
Net Debt		 8,516 8,940 8,763 9,874 9,814 9,817 9,914 10,136 10,033 9,177
Capital Expenditures (CapEx)		 16 18 15 30 34 52 15 13 11 6.62
Net Nonoperating Expense (NNE)		 431 712 334 910 429 -46 -92 75 253 -96
Net Nonoperating Obligations (NNO)		 8,848 9,216 9,369 10,099 10,064 10,157 10,238 10,438 10,268 9,476
Total Depreciation and Amortization (D&A)		 71 211 108 81 84 85 372 92 89 89
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.68) ($1.34) ($0.54) ($1.46) ($1.10) $0.19 ($0.07) $0.05 ($0.24) $0.37
Adjusted Weighted Average Basic Shares Outstanding		 600.25M 600.23M 600.06M 600.30M 598.52M 598.44M 598.34M 598.30M 598.63M 598.98M
Adjusted Diluted Earnings per Share		 ($0.68) ($1.34) ($0.54) ($1.46) ($1.10) $0.19 ($0.07) $0.05 ($0.24) $0.37
Adjusted Weighted Average Diluted Shares Outstanding		 600.25M 600.23M 600.06M 600.30M 598.52M 598.55M 598.34M 598.31M 598.84M 599.34M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.07) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 600.60M 600.40M 600.20M 600.10M 599.10M 599M 598.40M 598.30M 598.30M 598M
Normalized Net Operating Profit after Tax (NOPAT)		 19 -89 14 34 -235 71 -134 108 113 126
Normalized NOPAT Margin		 4.32% -74.29% 8.44% 12.61% 0.00% 35.69% -39.78% 30.91% 24.09% 47.77%
Pre Tax Income Margin		 -91.64% -662.21% -184.76% -318.61% 0.00% 63.52% -56.52% 10.44% -26.66% 91.05%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 -1.19 0.20 0.00 0.00 0.73 0.00 0.00 0.00 1.55
NOPAT to Interest Expense		 0.00 -0.84 0.14 0.00 0.00 0.67 0.00 0.00 0.00 1.43
EBIT Less CapEx to Interest Expense		 0.00 -1.37 0.05 0.00 0.00 0.24 0.00 0.00 0.00 1.48
NOPAT Less CapEx to Interest Expense		 0.00 -1.01 -0.01 0.00 0.00 0.18 0.00 0.00 0.00 1.36
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 -13.33% -13.69% -25.70% -36.30% -110.66% -2,133.72% 964.46% 229.13% 77.29% 55.30%
Augmented Payout Ratio		 -13.33% -13.69% -25.70% -36.30% -110.66% -2,133.72% 964.46% 229.13% 79.27% 55.30%

Frequently Asked Questions About Medical Properties Trust's Financials

When does Medical Properties Trust's fiscal year end?

According to the most recent income statement we have on file, Medical Properties Trust's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Medical Properties Trust's net income changed over the last 9 years?

Medical Properties Trust's net income appears to be on a downward trend, with a most recent value of -$2.41 billion in 2024, falling from $139.93 million in 2015. The previous period was -$556.09 million in 2023. Find out what analysts predict for Medical Properties Trust in the coming months.

How has Medical Properties Trust revenue changed over the last 9 years?

Over the last 9 years, Medical Properties Trust's total revenue changed from $441.88 million in 2015 to $995.55 million in 2024, a change of 125.3%.

How much debt does Medical Properties Trust have?

Medical Properties Trust's total liabilities were at $9.46 billion at the end of 2024, a 11.3% decrease from 2023, and a 170.1% increase since 2015.

How much cash does Medical Properties Trust have?

In the past 9 years, Medical Properties Trust's cash and equivalents has ranged from $83.24 million in 2016 to $1.46 billion in 2019, and is currently $332.34 million as of their latest financial filing in 2024.

How has Medical Properties Trust's book value per share changed over the last 9 years?

Over the last 9 years, Medical Properties Trust's book value per share changed from 8.84 in 2015 to 8.05 in 2024, a change of -8.9%.


Related Companies

This page (NYSE:MPW) was last updated on 6/1/2025 by MarketBeat.com Staff
From Our Partners
Banks aren’t ready for this altcoin—are you?
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...
Crypto 101 Media | Sponsored
Trump Just Gave the Green Light to Rewrite Social Security?
In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...
Altimetry | Sponsored
The “supermetal” that could power AI
While the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...
True Market Insiders | Sponsored
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...
Weiss Ratings | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
The Buffett Indicator is screaming, “sell stocks, buy gold”
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Crypto Is Pumping Again – Now Comes the Real Opportunity
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored